Register
Login:
Share:
Email Facebook Twitter


Exclusive: Hardman & Co call the lithium market: is a change in trend happening?
Tower Resources identify 18 million barrels of contingent reserves worth $118M in Cameroon


Synairgen Share Price (SNG)



Share Price Information for Synairgen (SNG)


Share Price: 14.50Bid: 14.00Ask: 15.00Change: 0.00 (0.00%)No Movement on Synairgen
Spread: 1.00Spread as %: 7.14%Open: 14.50High: 14.50Low: 14.50Yesterday’s Close: 14.50

Synairgen Plc Ord 1P

Synairgen is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
14.50
Share Price SpacerBid
14.00
Share Price SpacerAsk
15.00
Share Price SpacerChange
0%0.00
Share Price SpacerVolume
5,744
Share Price SpacerOpen
14.50
Share Price SpacerHigh
14.50
Share Price SpacerLow
14.50
Share Price SpacerClose
14.50
Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 109.32m £15.85m 10,000

52 Week High 26.50 52 Week High Date 4-JUL-2018
52 Week Low 10.50 52 Week Low Date 13-DEC-2017

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
1 0 5,744 7.513 1.93 0.00 0.00


London South East Users info for Synairgen




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

10-Dec-18
08:06:13
14.59
5,744
Buy* 
14.00
15.00
838.05
Trade Type:
Ordinary

07-Dec-18
13:01:05
14.59
1,280
Buy* 
14.00
15.00
186.75
Trade Type:
Ordinary

06-Dec-18
14:17:44
14.44
14,000
Sell* 
14.00
15.00
2,022
Trade Type:
Ordinary




View more Synairgen trades >>

Directors Deals for Synairgen (SNG)
Trade DateActionNotifierPriceCurrencyAmountHolding
12-Oct-18Buy
Trade Notifier Information for Synairgen
Richard J Marsden held the position of CEO at Synairgen at the time of this trade.
 Richard J Marsden
16GBX156,250310682
12-Oct-18Buy
Trade Notifier Information for Synairgen
John C Ward held the position of Finance Director at Synairgen at the time of this trade.
 John C Ward
16GBX62,500339006
12-Oct-18Buy
Trade Notifier Information for Synairgen
Phillip David Monk held the position of Chief Scientific Officer at Synairgen at the time of this trade.
 Phillip David Monk
16GBX46,875230314
View more Synairgen directors dealings >>


cadburyhill
Posts: 436
Opinion:Strong Buy
Price:14.50
AZN....
Fri 14:01
ever since AZN ditched us, they've had nothing but failures across their respiratory programme. I can't recall one respiratory success of theirs....does make you wonder if they'll be back to partner on COPD..

A phase 2a trial of AstraZeneca’s AZD1419 has missed its primary endpoint. AstraZeneca moved the Dynavax-partnered TLR9 agonist into the trial in the belief it could improve time to loss of asthma control in patients with eosinophilic, moderate-to-severe forms of the disease.
doggo
Posts: 2,513
Opinion:No Opinion
Price:14.50
RE: 23%
Wed 16:53
Don’t be silly how can you summize that?
RichTheNewbie
Posts: 19,033
Opinion:No Opinion
Price:14.50
RE: 23%
Wed 11:51
It might appear to be two massive buys but I think it's more likely to be a rollover.
Extremely hefty position size though to be rolling over (well over £500k).
Someone's still very confident.
destitute
Posts: 1,399
Opinion:No Opinion
Price:14.50
RE: 23%
Wed 11:24
Thats strange? Just had a comment questioning the 7m trade deleted. A £1m trade? Ideas anyone?
doggo
Posts: 2,513
Opinion:No Opinion
Price:14.50
23%
Tue 14:12
So going from 23% to a 22% holding is an increase is it?
View more share chat for Synairgen (SNG) >>




Synairgen Plc Ord 1P home pageWebsite: Synairgen Plc Ord 1P
Website Description: New Treatments for Respiratory Diseases - Synairgen Ltd



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.